Will the new CB₁ cannabinoid receptor antagonist SR-147778 have advantages over rimonabant?

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.14, Iss.3, 2005-03, pp. : 339-342

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Discriminative stimulus effects in rats of SR-141716 (rimonabant), a cannabinoid CB₁ receptor antagonist

By Järbe Torbjörn Harris Michele Li Chen Liu Qian Makriyannis Alexandros

Psychopharmacology, Vol. 177, Iss. 1-2, 2004-12 ,pp. : 35-45

Springer Publishing Company

Access to resources Recommend Favorite

Is the cannabinoid CB1 receptor antagonist rimonabant advancing the treatment of obesity?

By Doggrell Sheila A

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 12, 2005-10 ,pp. : 2141-2144

Informa Healthcare

Access to resources Recommend Favorite

Discriminative stimulus effects of the cannabinoid CB₁ receptor antagonist rimonabant in rats

By Järbe Torbjörn Li Chen Vadivel Subramanian Makriyannis Alexandros

Psychopharmacology, Vol. 198, Iss. 4, 2008-07 ,pp. : 467-478

Springer Publishing Company

Access to resources Recommend Favorite

Effects of the cannabinoid CB₁ receptor antagonist rimonabant on distinct measures of impulsive behavior in rats

By Pattij Tommy Janssen Mieke Schepers Inga González-Cuevas Gustavo Vries Taco Schoffelmeer Anton

Psychopharmacology, Vol. 193, Iss. 1, 2007-07 ,pp. : 85-96

Springer Publishing Company

Access to resources Recommend Favorite

The cannabinoid CB 1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2

By Darmani N.A.

European Journal of Pharmacology, Vol. 430, Iss. 1, 2001-10 ,pp. : 49-58

Elsevier

Access to resources Recommend Favorite